PGHLProcter & Gamble Health Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on PGHL — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 19.1% YoY
- • Profit growth: 54.6% YoY
- • ROE: 61.6%
- • Trend strength (ADX): 27
- • Volatility: 25% annualized
- • Liquidity: ₹7.2 cr avg turnover
Bull case
- • Revenue growth: 19.1% YoY
- • Profit growth: 54.6% YoY
- • ROE: 61.6%
- • Trend strength (ADX): 27
Bear case
- • RSI: 35
- • MACD: bearish
- • 1-month return: -7.3%
- • 1-month vs NIFTY: -4.3% relative
Key risks
- • Momentum is fading versus the broader market
- • RSI: 35
- • MACD: bearish
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹160.38). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.